3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic ...

Checkpoint inhibitors act as a double-edged sword against cancer. Although they promote potent antitumor responses, they can also cause several adverse effects. This article joins a growing series on ...

Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" ...

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...

South Korean researchers have identified why immune checkpoint inhibitors fail to work against brain tumors such as ...

What is the work you’re leading at NextPoint as CSO? We’re developing therapies that harness the biology of the B7-H7 axis both as immunotherapies, targeted ...

Summary: Researchers demonstrated that the success of anti-CTLA-4 immunotherapy against brain tumors does not depend on local ...

Our immune system guards against cancer development by constantly surveilling the body and eliminating unhealthy cells. Immune cells are highly suspicious of other cells. While this leads to a swift ...